Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethylammonium SCHEMBL29000430 | 1.00 | CES2 (0.48) | CES2KMT2AMEN1FAAHMAPK1 | |
| Trimethylammonium SCHEMBL26978127 | 1.00 | CES2 (0.48) | CES2KMT2AMEN1FAAHMAPK1 | |
| Trimethylammonium SCHEMBL466946 | 1.00 | CES2 (0.48) | CES2KMT2AMEN1FAAHMAPK1 | |
| Trimethylammonium SCHEMBL467213 | 1.00 | CES2 (0.48) | CES2KMT2AMEN1FAAHMAPK1 | |
| SCHEMBL15188717 | 0.94 | CES2 (0.53) | CES2KMT2AMEN1FAAHMAPK1 | |
| SCHEMBL29770831 | 0.94 | CES2 (0.53) | CES2KMT2AMEN1FAAHMAPK1 | |
| SCHEMBL2992800 | 0.94 | CES2 (0.53) | CES2KMT2AMEN1FAAHMAPK1 | |
| SCHEMBL2999996 | 0.94 | CES2 (0.53) | CES2KMT2AMEN1FAAHMAPK1 | |
| Methylamine SCHEMBL20788005 | 0.91 | CES2 (0.50) | CES2KMT2AMEN1FAAHMAPK1 | |
| Trimethylammonium SCHEMBL21055749 | 0.91 | FAAH (0.54) | KMT2AMEN1FAAHMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115136-A1 | MULTIPLE CEST CONTRAST IMAGING OF NOSE-TO-BRAIN DRUG DELIVERY USING CT-CONTRAST AGENT-LOADED LIPOSOMES | CITY UNIVERSITY OF HONG KONG (HK) | 2024-04-11 | — | — | US | claimed |
| US-20230039515-A1 | NANODROPLETS WITH IMPROVED PROPERTIES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-02-09 | — | — | US | claimed |
| CN-112237628-A | EBV-targeted LMP2-mRNA nano vaccine | 四川大学华西医院 | 2021-01-19 | — | — | CN | claimed |
| CN-112180079-A | Stable liposome particles and application thereof in immunoturbidimetric assay | 上海睿康生物科技有限公司 | 2021-01-05 | — | — | CN | claimed |
| US-9532950-B2 | Vector for pulmonary delivery, inducing agent, and uses | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2017-01-03 | — | — | US | claimed |
| EP-1033971-B1 | COMBINED CHEMO-IMMUNOTHERAPY WITH LIPOSOMAL DRUGS AND CYTOKINES | YISSUM RES DEV CO (IL) | 2009-09-09 | — | — | EP | claimed |
| US-20080131455-A1 | Antigen Delivery Compositions And Methods Of Use | PDS BIOTECHNOLOGY CORPORATION (US) | 2008-06-05 | — | — | US | claimed |
| US-7303881-B2 | Antigen delivery compositions and methods of use | PDS BIOTECHNOLOGY CORPORATION (US) | 2007-12-04 | — | — | US | claimed |
| US-20060029655-A1 | Method for preparation of vesicles loaded with biological material and different uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-02-09 | — | — | US | claimed |
| US-6787132-B1 | Combined chemo-immunotherapy with liposomal drugs and cytokines | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-09-07 | — | — | US | claimed |
| EP-1404298-A2 | A METHOD FOR PREPARATION OF VESICLES LOADED WITH BIOLOGICAL MATERIAL AND DIFFERENT USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-04-07 | — | — | EP | claimed |
| WO-2003000227-A2 | A METHOD FOR PREPARATION OF VESICLES LOADED WITH BIOLOGICAL MATERIAL AND DIFFERENT USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-01-03 | — | — | WO | claimed |
| EP-1033971-A1 | COMBINED CHEMO-IMMUNOTHERAPY WITH LIPOSOMAL DRUGS AND CYTOKINES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2000-09-13 | — | — | EP | claimed |
| WO-1999027908-A1 | COMBINED CHEMO-IMMUNOTHERAPY WITH LIPOSOMAL DRUGS AND CYTOKINES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1999-06-10 | — | — | WO | claimed |
| US-20240238398-A1 | IMMUNOGENIC COMPOSITION | GRIFFITH UNIVERSITY (AU) | 2024-07-18 | — | — | US | disclosed |
| CN-109913455-B | Small interfering RNA capable of treating cancer | 左志军 | 2024-05-28 | — | — | CN | disclosed |
| CN-117987412-A | SiRNA for inhibiting STAT3 gene expression | 成都先衍生物技术有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-5919480-A | IMMUNOSTIMULATING CYTOKINE EFFECTIVE TO ENHANCE THE IMMUNE RESPONSE. | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1999-07-06 | — | — | US | disclosed |
| WO-1999027908-A1 | COMBINED CHEMO-IMMUNOTHERAPY WITH LIPOSOMAL DRUGS AND CYTOKINES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1999-06-10 | — | — | WO | disclosed |
| WO-1997049423-A2 | LIPOSOMAL INFLUENZA VACCINE COMPOSITION AND METHOD | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080131455-A1 | Antigen Delivery Compositions And Methods Of Use | CD74, CD47, HAVCR2 | CES2 2578/4885KMT2A 3386/4885MEN1 1502/4885 |
| US-20240238398-A1 | IMMUNOGENIC COMPOSITION | CD47, CD74, CD14 | CES2 4654/4885KMT2A 3254/4885MEN1 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.